PMID- 33817089
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231110
IS  - 2391-5412 (Electronic)
IS  - 2391-5412 (Linking)
VI  - 13
DP  - 2018 Jan
TI  - Telmisartan Induces Osteosarcoma Cells Growth Inhibition and Apoptosis Via 
      Suppressing mTOR Pathway.
PG  - 242-249
LID - 10.1515/biol-2018-0029 [doi]
AB  - Osteosarcoma (OS) is a commonly occurring primary malignant bone cancer with 
      serious impact and high mortality, yet effective and safe therapy method not 
      available. The aim of the present study was to elucidate the antitumor effect of 
      telmisartan on human osteosarcoma cells in vitro and its underlying mechanism. 
      The proliferation effect of osteosarcoma cell lines U2OS was examined by Cell 
      Counting Kit-8. The invasive and migratory capabilities were determined by 
      transwell invasion and migration assay. The percentage of apoptotic cells were 
      detected by flow cytometric analysis and proteins related to apoptosis including 
      Bax, Bcl-2 and Cleaved Caspase-3 were examined by western blotting. The 
      expressions of mammalian target of rapamycin (mTOR) signaling relevant molecules 
      were detected by western blot assay. Telmisartan treatment caused dose-dependent 
      and time-dependent inhibition of proliferation and inducing anti-migration, 
      anti-invasiveness and apoptosis of U2OS cells. The induction of apoptosis was 
      confirmed concurring with the altered expression of proteins associated with the 
      apoptosis. Mechanistically, telmisartan suppresses mTOR activation. Telmisartan 
      can impede the growth, invasion, migration and induce the apoptosis of U2OS cell 
      probably through inhibiting the mTOR signaling pathway activation. Thus, 
      telmisartan is a potential drug for the prevention and treatment of human 
      osteosarcomal cancer.
CI  - (c) 2018 Chao Wang, Wen-Bo Wang, published by De Gruyter.
FAU - Wang, Chao
AU  - Wang C
AD  - The Third Department of Orthopedics, The First Affiliated Hospital of Harbin 
      Medical University, Harbin, Heilongjiang, 150001, China.
FAU - Wang, Wen-Bo
AU  - Wang WB
AD  - The Third Department of Orthopedics, The First Affiliated Hospital of Harbin 
      Medical University, Harbin, Heilongjiang, 150001, China.
LA  - eng
PT  - Journal Article
DEP - 20180705
PL  - Poland
TA  - Open Life Sci
JT  - Open life sciences
JID - 101669614
PMC - PMC7874731
OTO - NOTNLM
OT  - Telmisartan
OT  - apoptosis
OT  - mTOR signaling
OT  - osteosarcoma
OT  - proliferation
COIS- Conflict of interest: Authors state no conflict of interest.
EDAT- 2018/07/05 00:00
MHDA- 2018/07/05 00:01
PMCR- 2018/07/05
CRDT- 2021/04/05 06:13
PHST- 2017/12/11 00:00 [received]
PHST- 2018/03/28 00:00 [accepted]
PHST- 2021/04/05 06:13 [entrez]
PHST- 2018/07/05 00:00 [pubmed]
PHST- 2018/07/05 00:01 [medline]
PHST- 2018/07/05 00:00 [pmc-release]
AID - biol-2018-0029 [pii]
AID - 10.1515/biol-2018-0029 [doi]
PST - epublish
SO  - Open Life Sci. 2018 Jul 5;13:242-249. doi: 10.1515/biol-2018-0029. eCollection 
      2018 Jan.